Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. Show more
Location: 700 Quince Orchard Road, Gaithersburg, MD, 20878, United States | Website: https://www.novavax.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
1.108B
52 Wk Range
$5.01 - $17.81
Previous Close
$7.10
Open
$7.00
Volume
3,967,596
Day Range
$6.80 - $7.05
Enterprise Value
517.6M
Cash
731.5M
Avg Qtr Burn
-47.3M
Insider Ownership
8.78%
Institutional Own.
57.19%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Approved Update | ||
Nuvaxovid (NVX-CoV2373) Details COVID-19 | Approved Update | |
Approved Update | ||
Nuvaxovid (NVX-CoV2705) Details COVID-19 | Approved Update | |
COVID-Influenza combination (CIC) vaccine Details Influenza, COVID-19 | Phase 3 Data readout | |
Phase 3 Update | ||
NanoFlu vaccine Details Influenza | Phase 2 Update | |
RSV Vaccine Details Respiratory syncytial virus | Failed Discontinued | |
RSV Vaccine Details Respiratory syncytial virus | Failed Discontinued | |
RSV Vaccine Details Respiratory syncytial virus | Failed Discontinued |